Page results
-
Patient information who have been recommended to use a Biatain® dressing on your skin that has broken down due to your radiotherapy or proton beam therapy treatment.
-
Introduction of Bordetella pertussis PCR testing at Halo laboratory (Health Services Laboratories)
-
The North Central London Integrated Care System (NCL ICS) has new services and staff training to support patients with inherited red cell disorders, including Sickle Cell and Thalassaemia, living in Barnet, Camden, Enfield, Haringey and Islington.
-
Mr George Attilakos is a consultant in obstetrics and fetal medicine and the clinical lead for obstetrics at UCLH. Alongside managing normal pregnancies, Mr Attilakos has a special interest in the management of multiple pregnancies and high-risk pregnancies, as well as expertise in fetal medicine and fetal surgery, including in-utero treatment for congenital diaphragmatic hernia, spina bifida and twin-to-twin transfusion syndrome.
-
The North Central London Integrated Care System (NCL ICS) has new services and staff training to support patients with inherited red cell disorders, including Sickle Cell and Thalassaemia, living in Barnet, Camden, Enfield, Haringey and Islington.
-
Alison Clements, head of operations, patient flow and EPRR, has received a medal in recognition of her work to support NHS preparations for the Coronation of Charles III and Camilla last May.
-
Participants reacted quicker and made fewer errors during menstruation, despite believing their performance would be worse, according to new research from UCL and the Institute of Sport, Exercise & Health (ISEH).
-
UCLH Charity is delighted to announce that the Dangoor Family’s Exilarch’s Foundation has pledged a £1.2m gift to support the next phase of the development of the CAR T programme at University College London Hospitals NHS Foundation Trust (UCLH). The CAR T Speed Release Project aims to reduce the time between extracting patient’s stem cells and injecting re-engineered CAR T cells back into patients with cancer to fight cancer cells.
-
An immunotherapy drug given before surgery instead of chemotherapy meant that significantly more patients with a certain genetic profile were cancer free after surgery, according to clinical trial results presented by researchers at UCL and UCLH.
-
Patient information for Red Cell Network patients
File results
-
FOI/2023/0260 - Treatment for rare diseases: Fabry, Gaucher and Pompe disease and Hunter Syndrome
-
FOI/2023/0332 - Eating disorder services and Advance Decisions/ Directives to refuse medical treatment (ADRTs)
-
FOI/2023/0262 - Clinical trial participation
-
FOI/2023/0275 - Trust statistics on spiking
-
FOI/2019/16 Antenatal unit questionnaire
-
FOI2017320 Patients with Multiple Sclerosis treated with MS disease modifying drugs
-
FOI2017300 Sustainability and transformation
-
FOI2017315 Expenditure on reconciliation and validation of incomplete and missing RTT codes
-
FOI/2023/0242 - Treatment of Haemophilia A
-
FOI2017328 Use of variable rate intravenous insulin infusion